Antoine Ferry
Algemeen Directeur bij Laboratoires C.T.R.S. SAS
Profiel
Antoine Ferry is currently the Chairman & Chief Executive Officer at Laboratoires C.T.R.S.
SAS.
He is also the Director & Chief Medical Officer at Gene Signal International SA, starting in 2010.
Additionally, he holds the position of Director at Aterovax SA since 2007.
Dr. Ferry is the President of Hesperus AD, starting in 2014.
Previously, he served as the Chairman-Supervisory Board at Theraptosis SA.
Actieve functies van Antoine Ferry
Bedrijven | Functie | Begin |
---|---|---|
Gene Signal International SA
Gene Signal International SA Pharmaceuticals: MajorHealth Technology Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland. | Hoofd Techniek/Wetenschap/O&O | - |
Aterovax SA
Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Directeur/Bestuurslid | 01-02-2007 |
Laboratoires C.T.R.S. SAS
Laboratoires C.T.R.S. SAS Pharmaceuticals: MajorHealth Technology Laboratoires C.T.R.S. SAS is a French pharmaceutical company that manufactures pharmaceutical products. The company is based in Boulogne-Billancourt, France. The company was founded in 2002 by Bernard Deschamps. The CEO is Antoine Ferry. | Algemeen Directeur | - |
Hesperus AD | President | 22-01-2014 |
Eerdere bekende functies van Antoine Ferry
Bedrijven | Functie | Einde |
---|---|---|
Theraptosis SA
Theraptosis SA Pharmaceuticals: MajorHealth Technology Theraptosis S.A. , a biotechnology company, was founded in April 2001. Theraptosis designs and develops various drugs that act on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases. The Company's key assets include a dual technology platform (CytoTrust™ and MitoTrust™) for screening and targeting purposes and a pipeline of products in the areas of CNS and oncology. Theraptosis' discovery engines integrate mitochondria, and apoptosis expertise, and has developed pre-clinical animal models. | Voorzitter | 10-03-2010 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Theraptosis SA
Theraptosis SA Pharmaceuticals: MajorHealth Technology Theraptosis S.A. , a biotechnology company, was founded in April 2001. Theraptosis designs and develops various drugs that act on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases. The Company's key assets include a dual technology platform (CytoTrust™ and MitoTrust™) for screening and targeting purposes and a pipeline of products in the areas of CNS and oncology. Theraptosis' discovery engines integrate mitochondria, and apoptosis expertise, and has developed pre-clinical animal models. | Health Technology |
Gene Signal International SA
Gene Signal International SA Pharmaceuticals: MajorHealth Technology Gene Signal International SA engages in the development of drugs to manage angiogenesis based conditions. It is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. The company was founded by Eric Viaud, Salman Al-Mahmood, and Eric Thorin in 2000 and is headquartered in Lausanne, Switzerland. | Health Technology |
Aterovax SA
Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Health Services |
Laboratoires C.T.R.S. SAS
Laboratoires C.T.R.S. SAS Pharmaceuticals: MajorHealth Technology Laboratoires C.T.R.S. SAS is a French pharmaceutical company that manufactures pharmaceutical products. The company is based in Boulogne-Billancourt, France. The company was founded in 2002 by Bernard Deschamps. The CEO is Antoine Ferry. | Health Technology |
Hesperus AD |